Ironwood Pharmaceuticals (IRWD) EBITDA Margin (2010 - 2026)
Ironwood Pharmaceuticals' (IRWD) quarterly EBITDA Margin came in at 70.16% in Q2 2026, up 1699.0% year-over-year from 3.9% in Q2 2025, and up 2.96% quarter-over-quarter from 68.14% in Q1 2026.
Powered by 
Analysis
Ironwood Pharmaceuticals (IRWD) EBITDA Margin (2010 - 2026) Analysis & Trends
Ironwood Pharmaceuticals has disclosed EBITDA Margin across 17 years of filings, most recently posting 70.16% for Q2 2026.
- In Q2 2026, EBITDA Margin rose 1699.0% year-over-year to 70.16%; the TTM figure through Jun 2026 stood at 60.15% (up 3638.0% YoY), while the FY2025 annual figure was 33.26%, up 676.0% from the prior year.
- EBITDA Margin came in at 70.16% for Q2 2026 at Ironwood Pharmaceuticals, up from 68.14% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 70.16% in Q2 2026 to a low of 1008.68% in Q2 2023.
- Average EBITDA Margin over 5 years is 18.87%, with a median of 44.18% recorded in 2025.
- Year-over-year, EBITDA Margin tumbled 106592 bps in 2023 and surged 103514 bps in 2024.
- Over 5 years, EBITDA Margin stood at 63.77% in 2022, then tumbled by 50 bps to 31.98% in 2023, then gained by 9 bps to 34.78% in 2024, then plunged by 59 bps to 14.26% in 2025, then jumped by 392 bps to 70.16% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 70.16% in Q2 2026, 68.14% in Q1 2026, and 14.26% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -25,380.93% |
| 10 | Ironwood Pharmaceuticals | 669.13 Mn | 590.00 Mn | - | 70.16% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 70.16% |
| Mar 31, 2026 | 68.14% |
| Dec 31, 2025 | 14.26% |
| Sep 30, 2025 | 61.84% |
| Jun 30, 2025 | 53.17% |
| Mar 31, 2025 | -70.75% |
| Dec 31, 2024 | 34.78% |
| Sep 30, 2024 | 27.99% |
| Jun 30, 2024 | 26.46% |
| Mar 31, 2024 | 14.72% |
| Dec 31, 2023 | 31.98% |
| Sep 30, 2023 | 35.19% |
| Jun 30, 2023 | -1,008.68% |
| Mar 31, 2023 | 57.75% |
| Dec 31, 2022 | 63.77% |
| Sep 30, 2022 | 63.03% |
| Jun 30, 2022 | 57.24% |
| Mar 31, 2022 | 59.31% |
| Dec 31, 2021 | 48.32% |
| Sep 30, 2021 | 62.82% |